Tian-Ao Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tian-Ao Xie has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Xin Yin
Department of Clinical Laboratory Medicine The Third Affiliated Hospital of Guangzhou Medical University Guangzhou China
2 shared publications - Xu-Guang Guo
Department of Clinical Medicine, The Third Clinical School of Guangzhou Medical University, Guangzhou, China
2 shared publications - Bin Zhang
Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China
1 shared publication - Jiahao Hu
Institute of Pharmaceutics College of Pharmaceutical Sciences Zhejiang University 866 Yu‐Hang‐Tang Road Hangzhou 310058 China
1 shared publication - Jian-Wen Su
Department of Clinical Laboratory Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
1 shared publication - Jiasheng Cao
Center for X-mechanics, Department of Engineering Mechanics, Zhejiang University, Hangzhou, China
1 shared publication
Latest Publications
- 27 February 2023
- Published by Taylor & Francis in Immunotherapy
- Vol. 15 (5) , 353-365
Evaluation of PD-L1 as a Biomarker for Immunotherapy for Hepatocellular Carcinoma: Systematic Review and Meta-Analysis
Aim: To determine if PD-L1 can be used as a biomarker to predict the efficacy of anti-PD-1/PD-L1 inhibitors in hepatocellular carcinoma (HCC). Methods: Relevant studies from a specific search of th... Plain language summary Clinically, liver cancer patients with high PD-L1 levels may not benefit from immunotherapy. Conversely, some patients with low PD-L1 level can benefit from it. Therefore, th...
- 27 February 2023
- Published by Taylor & Francis in Immunotherapy
- Vol. 15 (5) , 353-365
Evaluation of PD-L1 as a Biomarker for Immunotherapy for Hepatocellular Carcinoma: Systematic Review and Meta-Analysis
Aim: To determine if PD-L1 can be used as a biomarker to predict the efficacy of anti-PD-1/PD-L1 inhibitors in hepatocellular carcinoma (HCC). Methods: Relevant studies from a specific search of th... Plain language summary Clinically, liver cancer patients with high PD-L1 levels may not benefit from immunotherapy. Conversely, some patients with low PD-L1 level can benefit from it. Therefore, th...
- Open Access
- 1 January 2022
- Published by XMLink in Yonsei Medical Journal
- Vol. 63 (5) , 480-489
Evaluation of CRISPR-Based Assays for Rapid Detection of SARS-CoV-2: A Systematic Review and Meta-Analysis
Huang PY, et al. Yonsei Med J. 2022 May;63(5):480-489. https://doi.org/10.3349/ymj.2022.63.5.480
- 1 January 2022
- Published by XMLink in Yonsei Medical Journal
- Vol. 63 (5) , 480-489
Open AccessEvaluation of CRISPR-Based Assays for Rapid Detection of SARS-CoV-2: A Systematic Review and Meta-Analysis
Huang PY, et al. Yonsei Med J. 2022 May;63(5):480-489. https://doi.org/10.3349/ymj.2022.63.5.480
- Open Access
- 1 January 2022
- Published by XMLink in Yonsei Medical Journal
- Vol. 63 (1) , 95-103
Meta-Analysis of the Diagnostic Efficacy of the Luminex xTAG Respiratory Viral Panel FAST v2 Assay for Respiratory Viral Infections
Xie LM, et al. Yonsei Med J. 2022 Jan;63(1):95-103. https://doi.org/10.3349/ymj.2022.63.1.95
- 1 January 2022
- Published by XMLink in Yonsei Medical Journal
- Vol. 63 (1) , 95-103
Open AccessMeta-Analysis of the Diagnostic Efficacy of the Luminex xTAG Respiratory Viral Panel FAST v2 Assay for Respiratory Viral Infections
Xie LM, et al. Yonsei Med J. 2022 Jan;63(1):95-103. https://doi.org/10.3349/ymj.2022.63.1.95